Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, shares insights into the importance of enrolling patients with amyloidosis in clinical trials, and further comments on how this may improve outcomes for these patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.